Legis Daily

GENE Therapy Payment Act

USA116th CongressHR-5882| House 
| Updated: 2/12/2020
Kurt Schrader

Kurt Schrader

Democratic Representative

Oregon

Cosponsors (6)
David Schweikert (Republican)Roger Marshall (Republican)Markwayne Mullin (Republican)Mike Kelly (Republican)Ami Bera (Democratic)Jason Crow (Democratic)

Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 12, 2020
Introduced in House
Feb 12, 2020
Referred to the House Committee on Energy and Commerce.
  • February 12, 2020
    Introduced in House


  • February 12, 2020
    Referred to the House Committee on Energy and Commerce.

Health

Related Bills

  • S 116-2543: Prescription Drug Pricing Reduction Act of 2019
  • S 116-4199: Prescription Drug Pricing Reduction Act of 2020
  • HR 116-19: Lower Costs, More Cures Act of 2019
Administrative law and regulatory proceduresAppropriationsCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyGeneticsGovernment studies and investigationsHealth care costs and insuranceHome and outpatient careIntergovernmental relationsManufacturingMedicaidPrescription drugsState and local government operations

GENE Therapy Payment Act

USA116th CongressHR-5882| House 
| Updated: 2/12/2020
Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 12, 2020
Introduced in House
Feb 12, 2020
Referred to the House Committee on Energy and Commerce.
  • February 12, 2020
    Introduced in House


  • February 12, 2020
    Referred to the House Committee on Energy and Commerce.
Kurt Schrader

Kurt Schrader

Democratic Representative

Oregon

Cosponsors (6)
David Schweikert (Republican)Roger Marshall (Republican)Markwayne Mullin (Republican)Mike Kelly (Republican)Ami Bera (Democratic)Jason Crow (Democratic)

Energy and Commerce Committee

Health

Related Bills

  • S 116-2543: Prescription Drug Pricing Reduction Act of 2019
  • S 116-4199: Prescription Drug Pricing Reduction Act of 2020
  • HR 116-19: Lower Costs, More Cures Act of 2019
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative law and regulatory proceduresAppropriationsCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug therapyGeneticsGovernment studies and investigationsHealth care costs and insuranceHome and outpatient careIntergovernmental relationsManufacturingMedicaidPrescription drugsState and local government operations